trastuzumab
astrazeneca,daiichi sankyo
['breast', 'trastuzumab']
the hits just keep coming for trastuzumab - 20+ years after 1st approval of the her2 targeting antibody, incredible results in a new breast cancer population. 
Transformation & transcendence through biotechnology. https://t.co/gI5AiWSqUm @lab_dao